Lymphoma is a highly heterogeneous group of hematologic malignancies and a major disease context for precision medicine and targeted signaling-pathway therapies. Its biology is driven by several recurrent survival and oncogenic networks, including b cell receptor signaling, phosphatidylinositol 3 kinase/AKT/mTOR, mammalian target of rapamycin, b cell lymphoma 2, janus kinase, and signal transducer and activator of transcription pathways. Targeted therapies have revolutionized treatment in this setting and have enabled chemotherapy-free regimens, reflecting the central role of pathway inhibition in disease control. Lymphoma is also a setting for immunotherapy advances, including bispecific T-cell engagers and oncolytic virus approaches such as vaccinia virus. Recent work has further linked myd88-mutant lymphomas to distinct immune microenvironment states that associate with therapeutic response, and has highlighted post-CAR T cell therapy lymphoproliferative complications as an emerging diagnostic challenge.
Targeted signaling and precision medicine
- A 2026 Chinese Medical Journal review (PMID:41736531) framed lymphoma as a heterogeneous hematologic malignancy in which targeted signaling-pathway therapies and precision medicine have produced major clinical breakthroughs.
- b cell receptor signaling was described as a foundational survival network governing lymphoma cell survival and proliferation, alongside phosphatidylinositol 3 kinase/AKT/mTOR and mammalian target of rapamycin pathways. (PMID:41736531)
- b cell lymphoma 2, janus kinase, and signal transducer and activator of transcription signaling were highlighted as key regulatory or oncogenic drivers in lymphoma. (PMID:41736531)
- The same review emphasized that targeted therapies have enabled chemotherapy-free regimens in lymphoma. (PMID:41736531)
Immunotherapy and cellular therapy
- Bispecific T-cell engager therapy was noted as having shown significant efficacy in hematologic malignancy settings, including lymphoma-relevant disease contexts. (PMID:41806779)
- A 2026 Cancer Immunology, Immunotherapy study (PMID:42012649) evaluated an IL-18-armed oncolytic vaccinia virus as an immunotherapy for lymphoma.
- That study reported remodeling of the suppressive microenvironment through macrophage and Treg modulation, supporting immune reprogramming as a therapeutic mechanism. (PMID:42012649)
- Post-CAR T cell therapy lymphoproliferative disorders were reviewed as a spectrum of lymphoma-like complications, including CAR-transgene-positive and transgene-negative cases. (PMID:41986503)
Molecular subtypes and microenvironment
- A 2026 Molecular Cancer study (PMID:42010569) analyzed genetically driven immune microenvironment states in myd88-mutant lymphomas.
- Those immune states were associated with therapeutic responses, linking genotype to treatment sensitivity. (PMID:42010569)
- The study adds to evidence that lymphoma outcomes are shaped not only by tumor-intrinsic signaling but also by the surrounding immune ecosystem. (PMID:42010569)
- This subtype-focused work complements broader pathway-based models of lymphoma biology. (PMID:41736531)